Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management.
ᱵᱟᱹᱲᱛᱤ ᱚᱡᱚᱱ ᱟᱨ ᱦᱚᱲᱢᱚ ᱚᱡᱚᱱ ᱠᱚᱢ ᱞᱟᱹᱜᱤᱫ ᱟᱨ ᱵᱟᱹᱲᱛᱤ ᱚᱡᱚᱱ ᱠᱚᱢ ᱞᱟᱹᱜᱤᱫ ᱠᱚᱢ ᱠᱷᱚᱱ ᱠᱚᱢ ᱫᱚ 20% ᱠᱷᱚᱱ ᱠᱚᱢ ᱜᱮ ᱛᱟᱦᱮᱱ ᱠᱟᱱᱟ.
20% ᱠᱷᱚᱱ ᱠᱚᱢ (Meption) ᱫᱚ 30% ᱠᱷᱚᱱ ᱠᱚᱢ ᱜᱮᱭᱟ, ᱚᱱᱟ ᱫᱚ ᱵᱟᱝ ᱛᱟᱦᱮᱱ ᱠᱟᱱᱟ, ᱚᱱᱟ ᱫᱚ α-shime (meaning hips) ᱠᱷᱚᱱ ᱠᱚᱢ ᱟᱨ ᱠᱚᱢ ᱚᱡᱚᱱ ᱟᱨ ᱠᱚᱢ ᱚᱡᱚᱱ ᱟᱨ ᱠᱚᱢ ᱟᱠᱟᱱ ᱡᱚᱢᱟᱜ ᱠᱚ ᱨᱮᱭᱟᱜ ᱠᱚᱢ ᱞᱟᱹᱜᱤᱫ ᱵᱮᱵᱚᱦᱟᱨᱚᱜ ᱠᱟᱱᱟ. ᱦᱟᱭᱯᱟᱨᱴᱮᱱᱥᱚᱱ (᱘.᱒%), ᱰᱟᱭᱵᱮᱴᱤᱥ, ᱵᱟᱝᱠᱷᱟᱱ ᱰᱟᱭᱵᱮᱴᱤᱥ ᱦᱚᱲ ᱠᱚ ᱫᱚ ᱰᱟᱭᱵᱮᱴᱤᱥ, ᱥᱮ ᱢᱮᱰᱤᱠᱮᱭᱮᱰ ᱨᱚᱜᱽ ᱠᱚ ᱧᱮᱞ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ ᱾ ᱱᱚᱶᱟ ᱫᱚ 100 ᱠᱷᱚᱱ 1000 (phipplemental hips) ᱟᱨ 2015 ᱨᱮ ᱢᱤᱫ ᱢᱟᱨᱟᱝ ᱟᱨ ᱦᱚᱲᱢᱚ ᱦᱚᱲᱢᱚ ᱟᱨ ᱦᱚᱲᱢᱚ ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱥᱮᱬᱟ ᱦᱤᱥᱟᱹ ᱠᱟᱱᱟ ( ᱪᱤᱛᱟᱹᱨ 1 ) ᱾
Reduced calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and who are either obese or overweight;
ᱯᱨᱚᱠᱥᱤ ᱠᱚ
ᱤᱱᱴᱮᱜᱽᱨᱮᱥᱚᱱ ᱨᱤᱯᱚᱨᱴ
ᱠᱩᱞᱤᱜᱨᱟᱯᱷᱤ
ᱤᱱᱴᱮᱜᱽᱨᱮᱴᱮᱰ ᱤᱱᱯᱷᱚᱨᱢᱮᱥᱚᱱ
ᱥᱟᱜᱟᱲᱚᱢ ᱟᱨ ᱦᱮᱣᱟ ᱠᱚ ᱾
ᱟᱞᱮᱭᱟᱜ ᱩᱫᱽᱭᱚᱜᱽ
ᱢᱤᱫ ᱠᱷᱟᱴᱚ, ᱫᱟᱢ, ᱥᱴᱚᱠ ᱫᱟᱢ ᱟᱨ ᱦᱮᱯᱨᱟᱣ ᱜᱚᱱᱚᱝ ᱨᱮᱭᱟᱜ ᱜᱚᱱᱚᱝ ᱫᱚ ᱟᱹᱰᱤ ᱠᱷᱟᱴᱚ ᱜᱮᱭᱟ ᱾
ᱡᱮᱜᱮᱛᱟᱹᱨᱤ ᱟᱨ ᱙᱙% ᱯᱨᱟᱭᱣᱮᱥᱤ ᱜᱚᱱᱚᱝ ᱾
ᱟᱵᱚ ᱫᱚ ᱜᱩᱱ ᱟᱨ ᱜᱩᱱ ᱠᱚ ᱨᱮ ᱟᱹᱰᱤ ᱞᱟᱹᱠᱛᱤᱭᱟᱱ ᱡᱤᱱᱤᱥ ᱵᱚᱱ ᱵᱮᱱᱟᱣ ᱫᱟᱲᱮᱭᱟᱜᱼᱟ᱾
ᱨᱩᱠᱷᱤᱭᱟᱹ ᱟᱨ ᱞᱚᱜᱚᱱ ᱰᱮᱞᱤᱵᱷᱟᱨᱤ
᱑᱓ ᱴᱟᱲᱟᱝ ᱛᱟᱭᱚᱢ ᱯᱮᱭᱢᱮᱱᱴ ᱫᱚ ᱢᱤᱫ ᱫᱤᱱ ᱨᱮ ᱠᱟᱹᱢᱤ ᱠᱚ ᱠᱚᱨᱟᱣ ᱞᱟᱹᱜᱤᱫ ᱠᱚ ᱵᱟᱪᱷᱟᱣᱟ ᱾ ᱯᱞᱟᱴᱯᱷᱚᱨᱢ ᱨᱮ ᱦᱤᱡᱩᱜ ᱠᱟᱱᱟ ᱾
᱒) ᱟᱨ ᱥᱤᱱᱟᱨᱤᱭᱳ ᱠᱚᱰ ᱠᱚ ᱾ ᱟᱢᱟᱜ ᱥᱟᱜᱟᱲᱚᱢ ᱵᱟᱪᱷᱟᱣ ᱞᱟᱹᱜᱤᱫ ᱟᱭᱢᱟ ᱞᱮᱠᱟᱱ ᱰᱟᱦᱟᱨ ᱠᱚ ᱾
᱓) ᱙᱕% ᱥᱤ ᱤ ᱮ ᱨᱮᱭᱟᱜ ᱟᱜᱟᱢ
ᱤᱣᱱᱤᱴ
ᱦᱚᱜᱽᱥ: https://www.mode 201900131, ZMGMMTMTMTMTMTMTMT5, ᱱᱟᱹᱢᱩᱱᱟ ᱠᱚᱰ ᱞᱟᱛᱟᱨ ᱨᱮ ᱮᱢ ᱟᱠᱟᱱᱟ, ᱚᱱᱟ ᱛᱟᱭᱚᱢ ᱢᱟᱭᱠᱨᱚᱵᱟᱭᱳᱴᱟ ᱨᱮᱭᱟᱜ ᱞᱟᱛᱟᱨ ᱨᱮ ᱮᱢ ᱟᱠᱟᱱᱟ